Norway · Delayed Price · Currency is NOK ArcticZymes Technologies ASA Earnings Call Transcripts
Fiscal Year 2026
-
The company is executing a strategy to scale its enzyme platform through diversification, innovation, and customer-centric solutions, targeting high-growth markets like metagenomics and RNA therapeutics. Strong financials, validated customer impact, and a focus on operational leverage underpin ambitions for double-digit growth and market outperformance.
Fiscal Year 2025
-
Q4 and full year 2025 delivered strong revenue and EBITDA growth, driven by commercial transformation, product portfolio expansion, and strategic partnerships. Biomanufacturing and molecular tools segments both showed robust performance, with momentum expected to continue into 2026.
-
Q3 saw 24% revenue growth and a return to profitability, driven by strong molecular tools and biomanufacturing performance. A major European partnership and robust cash position set the stage for long-term growth, with new applications and markets fueling future expansion.
-
Q2 saw 5% revenue growth and a 50% EBITDA increase, driven by record biomanufacturing sales and the launch of M-SAN HQ GMP. Molecular tools faced a temporary dip but are set for recovery as key customers return. Strong cash reserves and strategic investments position the company for continued growth.
-
Q1 2025 revenue declined due to a temporary drop from a major OEM customer, but biomanufacturing sales grew 21% year-over-year and the customer base reached record highs. Strategic investments in commercial transformation and new CDMO partnerships are driving future growth.
Fiscal Year 2024
-
Q4 2024 saw revenue of NOK 24.4 million and EBITDA of NOK 2.7 million, with improved margins and a broader customer base despite a year-over-year decline. Strategic transformation, new product launches, and a strong cash position set the stage for growth in 2025.
-
Q3 saw a revenue decline to NOK 23.3 million and negative EBITDA, mainly due to weak Molecular Tools sales and challenging market conditions. Biomanufacturing showed growth, and strategic investments in commercial transformation and new product launches are expected to drive future performance.
-
Q2 2024 saw record order volume and steady progress in innovation, partnerships, and regulatory compliance, despite a slight revenue decline. New product launches and partnership deals are expected to drive future growth, with strong liquidity supporting ongoing investments.